NCT05232552

Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma

Safety and Efficacy of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma: a Phase 2 Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

anlotinib was added to TP inductive chemotherapy and definitive chemoradiation in nasopharyngeal carcinoma patients with N2-3 disease with necrosis or/and ECM

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	Anlotinib hydrochloride	anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
DRUG	induction chemotherapy	docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
RADIATION	concurrent chemoradiation	definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days

Timeline

• Start date: 2021-01-01
• Primary completion: 2022-12-31
• Completion: 2024-12-31
• First posted: 2022-02-10
• Last updated: 2022-02-10

Locations

1 site across 1 country: China